The FDA’s rejection of ivonescimab turns entirely on one missing number: a statistically significant overall survival benefit. The agency issued a Complete Response Letter on November 15, 2026, blocking Summit Therapeutics’ Biologics License Application for ivonescimab combined with platinum-containing chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer who progressed after EGFR tyrosine kinase inhibitor therapy. The FDA’s position was direct: progression-free survival improvement alone does not establish a positive benefit-risk profile sufficient for approval.

The CRL cites efficacy as the basis for rejection, specifically the absence of a statistically significant OS result. It rejects it on efficacy, specifically the absence of a statistically significant OS result. That is a high bar to clear in a resubmission. The HARMONi Phase 3 trial evaluated ivonescimab plus chemotherapy against placebo plus chemotherapy in patients with advanced EGFR-mutated NSCLC after TKI failure, and while PFS data supported the BLA package, the FDA’s recent draft guidance on OS in oncology treats overall survival as both an efficacy and a safety endpoint, not a secondary confirmation. Submitting a PFS-led package without mature OS data was a risk that did not pay off.

The practical question for Summit now is whether the HARMONi data set contains maturing OS results that could support a resubmission, or whether the company needs to run additional follow-up. A confirmatory OS analysis takes time patients in this population often do not have. Post-TKI EGFR-mutant NSCLC remains an area of significant unmet need, and this patient population has few well-validated options after first-line targeted therapy fails. The CRL does not close the door on ivonescimab, but it means no patients in the U.S. get access under an approved label until Summit can answer the OS question to the FDA’s satisfaction.

The specific number to track from here is the OS hazard ratio and its confidence interval when Summit discloses the updated HARMONi survival data. That figure will determine whether a resubmission is viable on the existing trial or whether the program needs a new study to reach approval.

Source link: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000092/smmt-20261115.htm

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.